Fundraising Fox
Antiva Biosciences
Redwood City, US · Founded 2012 · Delaware corporation · 19 employees on LinkedIn · 13 known investors
Find your way into Antiva Biosciences
Sign up to see every warm intro you have to Antiva Biosciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Antiva Biosciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Antiva Biosciences develops a topical therapeutic for women with high-risk HPV infection and pre-cancerous cervical lesions, utilizing antiviral prodrug chemistry. The company targets an unmet clinical need where no approved therapeutic options currently exist.
Founders & leadership
Antiva Biosciences was founded in 2012 by Karl Y. Hostetler.
KY
Karl Y. HostetlerFounderKarl Y. Hostetler is an Executive Officer and Director at Antiva Biosciences. He holds board certifications in internal medicine and endocrinology & metabolism, and has expertise in medicinal chemistry, translational research, and antiviral drug discovery.
GM
Gail MaderisChairman of the BoardGail Maderis has held leadership positions at private and public biotechnology companies and non-profit organizations. She has board experience and expertise in strategy, team-building, pharma partnerships, and life sciences financing.
KB
Kristine BallChief Executive OfficerShe previously led Soteria Biotherapeutics as CEO and served as chief financial officer at Menlo Therapeutics, Relypsa, and KAI Pharmaceuticals, where she also held corporate strategy responsibilities. Her board service includes Oruka Therapeutics, Atreca, and Forty Seven.
EC
Elaine ChienChief Medical OfficerElaine Chien is a board-certified OB/GYN physician and chief medical officer at Antiva Biosciences with over 25 years in clinical practice and biopharma leadership across women's health, oncology, and rare diseases. She has led clinical development programs and regulatory interactions with the FDA, EMA, and MHRA across multiple therapeutic areas.
RG
Raju GadirajuChief Technical Officer2024–2025Raju Gadiraju is an executive officer at Antiva Biosciences with extensive experience in pharmaceutical product development, including formulation chemistry, analytical work, manufacturing processes, regulatory compliance, and clinical supply management across multiple therapeutic delivery routes.
JS
John SaywardExecutive
Board
BR
FS
Florencia SegalBoard director
BG
WH
DK
Investors · 13
Adjuvant Capitallisted by Adjuvant CapitalNew York · $10M – $25M
How we know: Adjuvant Capital's portfolio page · a partner's Signal profile · press coverage · open dataset · 5k.vc investor directory · Not right? Tell us
Avestria Ventureslisted by Avestria VenturesSan Francisco
How we know: Avestria Ventures's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
Brace Pharmalisted by Brace PharmaAtlanta
How we know: Brace Pharma's portfolio page · Not right? Tell us
Canaan Partnerslisted by Canaan PartnersStamford · $500K – $20Mvia Wende Hutton · board
How we know: Canaan Partners's portfolio page · a partner's Signal profile · board seat on SEC Form D · funding news · press coverage · open dataset · 5k.vc investor directory · Not right? Tell us
__Twitter.png)
Gaingelslisted by GaingelsNew York · $200K – $500K
How we know: funding news · gaingels.com · Not right? Tell us
GV (Google Ventures)listed by GV (Google Ventures)Mountain View · $250K – $50M
How we know: GV (Google Ventures)'s portfolio page · press coverage · open dataset · 5k.vc investor directory · Not right? Tell us
HBM Healthcare Investmentslisted by HBM Healthcare InvestmentsZug
How we know: HBM Healthcare Investments's portfolio page · Not right? Tell us
HBM Partnerslisted by HBM PartnersZug · $5M – $50M
How we know: HBM Partners's portfolio page · Not right? Tell us
Lumira Ventureslisted by Lumira VenturesToronto · $1M – $10M
How we know: Lumira Ventures's portfolio page · funding news · press coverage · Not right? Tell us
Mana Ventureslisted by Mana VenturesEstero
How we know: funding news · Not right? Tell us
MPM BioImpactlisted by MPM BioImpactBoston · $1M – $15M
How we know: MPM BioImpact's portfolio page · Not right? Tell us
OUP (Osage University Partners)listed by OUP (Osage University Partners)Bala Cynwyd · $1M – $20M
How we know: OUP (Osage University Partners)'s portfolio page · Not right? Tell us
Sofinnova Ventureslisted by Sofinnova VenturesMenlo Park · $100K – $15M
How we know: Sofinnova Ventures's portfolio page · press coverage · the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$95.7M disclosed across 7 rounds · 2014–2023
▶$38.5MraisedOct 2024 · 21 investors · BiotechnologyRule 506(b)
▶$38.5MraisedOct 2024 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Clifford SamuelDirector
- Beni RovinskiDirector
- Florencia SegalDirector
- Gail MaderisDirector
- Kristine BallExecutive Officer, Director
- Elaine ChienExecutive Officer
- Brian GoodmanDirector
- Wende HuttonDirector
- Sarah WalterExecutive Officer
- Raju GadirajuExecutive Officer
- Offering amount
- $53M
- Amount sold
- $38.5M
- First sale
- Apr 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15.6MraisedNov 2021 · 20 investors · BiotechnologyRule 506(b)
▶$15.6MraisedNov 2021 · 20 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gail MaderisExecutive Officer, Director
- Clifford SamuelDirector
- Oranee DanielsExecutive Officer
- Steven JamesDirector
- Benjamin RovinskiDirector
- Raju GadirajuExecutive Officer
- Sarah WalterExecutive Officer
- Jenny YipDirector
- Wende HuttonDirector
- Vinzenz PloererDirector
- David KabakoffDirector
- Offering amount
- $31M
- Amount sold
- $15.6M
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15MraisedJul 2018 · 8 investors · BiotechnologyRule 506(b)
▶$15MraisedJul 2018 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steven P. JamesDirector
- David Kabakoff, Ph.D.Director
- Raju Gadiraju, Ph.D.Executive Officer
- Michael D. CannonDirector
- Wende S. HuttonDirector
- Vinzenz PloererDirector
- Gail MaderisExecutive Officer, Director
- Oranee DanielsExecutive Officer
- Benjamin RovinskiDirector
- Ting JiaDirector
- Sarah WalterExecutive Officer
- Offering amount
- $15M
- Amount sold
- $15M
- First sale
- Jul 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$14.7MraisedAug 2017 · 15 investors · BiotechnologyRule 506(b)
▶$14.7MraisedAug 2017 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Wendee S. HuttonDirector
- Sarah WalterExecutive Officer
- Benjamin RovinskiDirector
- Raju Gadiraju, Ph.D.Executive Officer
- Steven P. JamesDirector
- David KabakoffDirector
- Vinzenz PloererDirector
- Gail MaderisExecutive Officer, Director
- Oranee DanielsExecutive Officer
- Michael D. CannonDirector
- Offering amount
- $25.9M
- Amount sold
- $14.7M
- First sale
- Feb 2017
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
▶$8.9MraisedJun 2015 · 26 investors · BiotechnologyRule 506(b)
▶$8.9MraisedJun 2015 · 26 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steven JamesDirector
- Wende HuttonDirector
- John SaywardExecutive Officer
- Michael CannonDirector
- David KabakoffDirector
- William RespessDirector
- Offering amount
- $16M
- Amount sold
- $8.9M
- Proceeds to insiders
- $18.3K
- First sale
- May 2015
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
▶$1.7MraisedDec 2014 · 19 investors · BiotechnologyRule 506(b)
▶$1.7MraisedDec 2014 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael J. SullivanExecutive Officer
- Michael D. CannonDirector
- Karl Y. HostetlerExecutive Officer, Director
- John W. SaywardExecutive Officer
- William L. RespessDirector
- Offering amount
- $2.5M
- Amount sold
- $1.7M
- Minimum investment
- $1
- First sale
- Dec 2014
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
▶$1.1MraisedJul 2014 · 14 investors · BiotechnologyRule 506(b)
▶$1.1MraisedJul 2014 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael J. SullivanExecutive Officer
- Karl Y. HostetlerExecutive Officer, Director
- Michael D. CannonDirector
- William L. RespessDirector
- Offering amount
- $1.3M
- Amount sold
- $1.1M
- First sale
- Jun 2014
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Antiva Biosciences went on to found or lead other companies.
Related companies · 6
Iovance BiotherapeuticsIovance develops TIL (tumor-infiltrating lymphocyte) therapy, a personalized cancer treatment that isolates immune cells from a patient's tumor, expands them in a centralized facility using proprietary manufacturing processes, and returns them for infusion back into the patient.
Artiva BiotherapeuticsArtiva Bio is a clinical-stage biotechnology company developing NK cell-based therapies for autoimmune diseases, designed to be manufactured at scale and delivered in community settings. The company's lead product, AlloNK, combines natural killer cells with B-cell targeted monoclonal antibodies to achieve deep B-cell depletion for disease remission.
Minerva BiotechnologiesMinerva Biotechnologies develops cancer and stem cell therapeutics, including cancer immunotherapies aimed at solid tumors and preventing cancer metastasis. The company also works on patient-derived stem cells for regenerative medicine.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Yuva BioscencesYuva Biosciences develops and licenses Y100, a cosmetic active ingredient that enhances mitochondrial health to reduce visible signs of aging for use in skincare and haircare products.
TherivabioTheriva Biologics is a clinical-stage company developing therapeutics for cancer and related diseases, including an oncolytic adenovirus platform (VCN-01) and enzyme-based candidates for gastrointestinal and systemic conditions (SYN-004, SYN-020). It is a publicly traded biopharmaceutical company (NYSE American: TOVX) focused on areas of high unmet medical need.
Companies working in the same space as Antiva Biosciences.
Frequently asked questions
- What does Antiva Biosciences do?
- Antiva Biosciences develops a topical therapeutic for women with high-risk HPV infection and pre-cancerous cervical lesions, utilizing antiviral prodrug chemistry. The company targets an unmet clinical need where no approved therapeutic options currently exist.
- Who founded Antiva Biosciences?
- Antiva Biosciences was founded by Karl Y. Hostetler in 2012.
- Who are Antiva Biosciences's investors?
- Antiva Biosciences's investors include Adjuvant Capital, Avestria Ventures, Brace Pharma, Canaan Partners, Gaingels, GV (Google Ventures), HBM Healthcare Investments, HBM Partners and 5 more.
- How much funding has Antiva Biosciences raised?
- Antiva Biosciences has disclosed $95.7M raised across 7 rounds.
- Where is Antiva Biosciences headquartered?
- Antiva Biosciences is headquartered in Redwood City, US.